A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

To join this study, you would need to be an adult between 18 and 99 years old. Your non-small cell lung cancer must have spread or be advanced, and critically, your cancer cells must be confirmed to be missing the MTAP gene. You also need to have tried at least one other treatment for your advanced cancer already, and it either didn't work well enough or your cancer came back.

Researchers will also need to review a sample of your cancer tissue. If you have been treated for brain tumours, you might still be able to join, as long as it was at least 14 days ago. Even if you have small, untreated brain tumours that aren't causing symptoms and don't need steroid treatment, you might still be considered.

However, you wouldn't be able to join if your cancer has certain other gene changes that can be treated with different targeted drugs (like EGFR, ALK, or BRAF). You also couldn't join if you've had major surgery recently (within the last 28 days), or if you have untreated brain tumours that are causing symptoms or are larger than 2cm.

The detailed information about what taking part involves is not provided in this summary. However, generally, participation in a clinical study like this would typically involve regular visits to the study clinic for check-ups, blood tests, and scans to monitor your health and how the treatment is working. You would be given the study drug, anvumetostat, as directed by the study team. The total duration of your participation would depend on how well you respond to the treatment and your overall health, but typically studies involve a treatment phase followed by a follow-up period to track your progress.